TY - JOUR AU - Spellberg, B. AU - Powers, J. H. AU - Brass, E. P. AU - Miller, L. G. AU - Edwards, J. E. PY - 2004 DA - 2004// TI - Trends in antimicrobial drug development: implications for the future JO - Clin Infect Dis VL - 38 UR - https://doi.org/10.1086/420937 DO - 10.1086/420937 ID - Spellberg2004 ER - TY - BOOK AU - Hirschler, B. PY - 2010 DA - 2010// TI - EU regulator calls for more antibiotic research ID - Hirschler2010 ER - TY - JOUR AU - Rice, L. B. PY - 2008 DA - 2008// TI - Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE JO - J Infect Dis VL - 197 UR - https://doi.org/10.1086/533452 DO - 10.1086/533452 ID - Rice2008 ER - TY - BOOK PY - 2009 DA - 2009// TI - The bacterial challenge: time to react, in ECDC / EMEA Joint Technical Report PB - European Centre for Disease Prevention and Control and European Medicines Agency CY - Stockholm ID - ref4 ER - TY - BOOK PY - 2011 DA - 2011// TI - The Generating Antibiotic Incentives Now Act of 2011 PB - Pew Trust CY - Washington, D.C. ID - ref5 ER - TY - BOOK PY - 2013 DA - 2013// TI - Antibiotic Resistance Threats in the United States. Threat Report PB - Centers for Disease Control and Prevention CY - Atlanta ID - ref6 ER - TY - JOUR AU - Morel, C. M. AU - Mossialos, E. PY - 2010 DA - 2010// TI - Stoking the antibiotic pipeline JO - BMJ VL - 340 UR - https://doi.org/10.1136/bmj.c2115 DO - 10.1136/bmj.c2115 ID - Morel2010 ER - TY - CHAP AU - Ridge, K. W. AU - Hand, K. AU - Sharland, M. AU - Abubakar, I. AU - Livermore, D. M. PY - 2013 DA - 2013// TI - Annual Report of the Chief Medical Officer. Volume Two, 2011. Infections and the rise of antimicrobial resistance BT - Antimicrobial Resistance PB - CMO CY - London ID - Ridge2013 ER - TY - JOUR AU - DiMasi, J. A. AU - Grabowski, H. G. AU - Vernon, J. PY - 2004 DA - 2004// TI - R&D costs and returns by therapeutic category JO - Drug Inf J VL - 38 ID - DiMasi2004 ER - TY - JOUR AU - Spellberg, B. AU - Blaser, M. PY - 2011 DA - 2011// TI - Combating antimicrobial resistance: policy recommendations to save lives JO - Clin Infect Dis VL - 52 ID - Spellberg2011 ER - TY - JOUR AU - Spellberg, B. AU - Guidos, R. AU - Gilbert, D. AU - Bradley, J. AU - Boucher, H. W. AU - Scheld, W. M. AU - Bartlett, J. G. AU - Edwards, J. PY - 2008 DA - 2008// TI - The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America JO - Clin Infect Dis VL - 46 UR - https://doi.org/10.1086/524891 DO - 10.1086/524891 ID - Spellberg2008 ER - TY - BOOK PY - 2011 DA - 2011// TI - Recommendations for future collaboration between the US and EU ID - ref12 ER - TY - BOOK AU - Usdin, S. PY - 2012 DA - 2012// TI - Antibiotics reset: GAIN Act, FDA stance only first steps to refilling antibiotic pipeline in U.S ID - Usdin2012 ER - TY - BOOK AU - Hirschler, B. PY - 2013 DA - 2013// TI - Analysis: Antibiotics crisis prompts rethink on risks, rewards PB - Reuters CY - London ID - Hirschler2013 ER - TY - STD TI - Wetzstein C: Antibiotic-resistant 'superbugs' alarm health care industry, in The Washington Times2013. Washington, DC, Available from: http://www.washingtontimes.com/news/2013/mar/19/antibiotic-resistant-superbugs-alarm-health-care-i/?page=all UR - http://www.washingtontimes.com/news/2013/mar/19/antibiotic-resistant-superbugs-alarm-health-care-i/?page=all ID - ref15 ER - TY - BOOK AU - Walsh, F. PY - 2013 DA - 2013// TI - Antibiotics resistance 'as big a risk as terrorism' - medical chief PB - BBC News CY - London ID - Walsh2013 ER - TY - JOUR AU - Cars, O. AU - Hogberg, L. D. AU - Murray, M. AU - Nordberg, O. AU - Sivaraman, S. AU - Lundborg, C. S. AU - So, A. D. AU - Tomson, G. PY - 2008 DA - 2008// TI - Meeting the challenge of antibiotic resistance JO - BMJ VL - 337 UR - https://doi.org/10.1136/bmj.a1438 DO - 10.1136/bmj.a1438 ID - Cars2008 ER - TY - BOOK AU - Moon, S. AU - MPA, P. D. PY - 2012 DA - 2012// TI - Report of the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination PB - XIX International AIDS Conference CY - Washington, DC ID - Moon2012 ER - TY - BOOK AU - Mossialos, E. AU - Morel, C. AU - Edwards, S. AU - Berenson, J. AU - Gemmill-Toyama, M. AU - Brogan, D. PY - 2010 DA - 2010// TI - Policies and incentives for promoting innovation in antibiotic research PB - World Health Organization CY - Copenhagen ID - Mossialos2010 ER - TY - CHAP AU - Towse, A. AU - Keuffel, E. AU - Kettler, H. E. AU - Ridley, D. B. ED - Danzon, P. ED - Nicholson, P. PY - 2011 DA - 2011// TI - Drugs and vaccines for developing countries BT - The Oxford Handbook of The Economics of the Biopharmaceutical Industry PB - Oxford University Press CY - Oxford ID - Towse2011 ER - TY - JOUR AU - Hecht, R. AU - Wilson, P. AU - Palriwala, A. PY - 2009 DA - 2009// TI - Improving health r&d financing for developing countries: a menu of innovative policy options JO - Health Aff VL - 28 UR - https://doi.org/10.1377/hlthaff.28.4.974 DO - 10.1377/hlthaff.28.4.974 ID - Hecht2009 ER - TY - JOUR AU - Towse, A. AU - Kettler, H. PY - 2005 DA - 2005// TI - Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies JO - Bull World Health Organ VL - 83 ID - Towse2005 ER - TY - BOOK AU - Kremer, M. PY - 2000 DA - 2000// TI - Creating Markets for New Vaccines Part II: Design Issues. National Bureau of Economic Research Working Paper Series ID - Kremer2000 ER - TY - JOUR AU - Adams, C. P. AU - Van Brantner,, V. PY - 2006 DA - 2006// TI - Estimating the cost of new drug development: is it really $802 Million? JO - Health Aff VL - 25 UR - https://doi.org/10.1377/hlthaff.25.2.420 DO - 10.1377/hlthaff.25.2.420 ID - Adams2006 ER - TY - JOUR AU - Berndt, E. R. AU - Hurvitz, J. A. PY - 2005 DA - 2005// TI - Vaccine advance-purchase agreements for low-income countries: practical issues JO - Health Aff VL - 24 UR - https://doi.org/10.1377/hlthaff.24.3.653 DO - 10.1377/hlthaff.24.3.653 ID - Berndt2005 ER - TY - BOOK AU - Kaplan, W. AU - Laing, R. PY - 2004 DA - 2004// TI - Priority Medicines for Europe and the World PB - World Health Organization, Department of Essential Drugs and Medicines Policy CY - Geneva ID - Kaplan2004 ER - TY - BOOK AU - Levine, R. AU - Kremer, M. AU - Albright, A. PY - 2005 DA - 2005// TI - Making Markets for Vaccines: Ideas to Action – The report of the Center for Global Development Advance Market Commitment Working Group ID - Levine2005 ER - TY - JOUR AU - Brogan, D. AU - Mossialos, E. PY - 2006 DA - 2006// TI - Applying the concepts of financial options to stimulate vaccine development JO - Nat Rev Drug Discov VL - 5 UR - https://doi.org/10.1038/nrd2035 DO - 10.1038/nrd2035 ID - Brogan2006 ER - TY - JOUR AU - Beaves, R. PY - 1988 DA - 1988// TI - Net present value and rate of return: implicit and explicit reinvestment assumptions JO - Eng Econ VL - 33 UR - https://doi.org/10.1080/00137918808966958 DO - 10.1080/00137918808966958 ID - Beaves1988 ER - TY - JOUR AU - Remer, D. S. AU - Nieto, A. P. PY - 1995 DA - 1995// TI - A compendium and comparison of 25 project evaluation techniques. Part 1: net present value and rate of return methods JO - Int J Prod Econ VL - 42 UR - https://doi.org/10.1016/0925-5273(95)00104-2 DO - 10.1016/0925-5273(95)00104-2 ID - Remer1995 ER - TY - BOOK AU - Sosa, A. D. J. PY - 2010 DA - 2010// TI - Antimicrobial resistance in developing countries PB - Springer CY - New York UR - https://doi.org/10.1007/978-0-387-89370-9 DO - 10.1007/978-0-387-89370-9 ID - Sosa2010 ER - TY - JOUR AU - Ramsey, F. P. PY - 1927 DA - 1927// TI - A contribution to the theory of taxation JO - Econ J VL - 37 UR - https://doi.org/10.2307/2222721 DO - 10.2307/2222721 ID - Ramsey1927 ER - TY - JOUR AU - Danzon, P. PY - 1998 DA - 1998// TI - The economics of parallel trade JO - Pharmacoeconomics VL - 13 UR - https://doi.org/10.2165/00019053-199813030-00004 DO - 10.2165/00019053-199813030-00004 ID - Danzon1998 ER - TY - JOUR AU - Cheng, J. PY - 2006 DA - 2006// TI - Optimal R&D Expenditure- A value maximization approach JO - Int Res J Finance Econ VL - 5 ID - Cheng2006 ER - TY - JOUR AU - Towse, A. AU - Sharma, P. PY - 2011 DA - 2011// TI - Incentives for R&D for New Antimicrobial Drugs JO - Int J Econ Bus VL - 18 UR - https://doi.org/10.1080/13571516.2011.584434 DO - 10.1080/13571516.2011.584434 ID - Towse2011 ER - TY - JOUR AU - DiMasi, J. A. AU - Feldman, L. AU - Seckler, A. AU - Wilson, A. PY - 2010 DA - 2010// TI - Trends in risks associated with new drug development: success rates for investigational drugs JO - Clin Pharmacol Ther VL - 87 UR - https://doi.org/10.1038/clpt.2009.295 DO - 10.1038/clpt.2009.295 ID - DiMasi2010 ER - TY - JOUR AU - Spellberg, B. AU - Sharma, P. AU - Rex, J. H. PY - 2012 DA - 2012// TI - The critical impact of time discounting on economic incentives to overcome the antibiotic market failure JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3560-c1 DO - 10.1038/nrd3560-c1 ID - Spellberg2012 ER - TY - BOOK PY - 2013 DA - 2013// TI - Innovative Medicines Initiative ID - ref38 ER - TY - BOOK AU - Stafford, N. PY - 2012 DA - 2012// TI - €224 million EU antibiotics initiative launched, in Chemistry World ID - Stafford2012 ER - TY - BOOK PY - 2013 DA - 2013// TI - IMI Launches Antimicrobial resistance (AMR) projects to revitalise antibiotic development PB - EFPIA CY - Brussels ID - ref40 ER - TY - JOUR AU - Danzon, P. M. AU - Nicholson, S. AU - Pereira, N. S. PY - 2005 DA - 2005// TI - Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances. National Bureau of Economic Research Working Paper Series, 2003. No. 9615 (also published as Danzon, Patricia M., Sean Nicholson and Nuno Sousa Pereira. "Productivity In Pharmaceutical-Biotechnology R&D: The Role Of Experience And Alliances," JO - J Health Econ VL - 24 UR - https://doi.org/10.1016/j.jhealeco.2004.09.006 DO - 10.1016/j.jhealeco.2004.09.006 ID - Danzon2005 ER - TY - BOOK AU - Hollis, A. AU - Pogge, T. PY - 2008 DA - 2008// TI - Making New Medicines Accessible for All. A Report of Incentives for Global Health ID - Hollis2008 ER - TY - JOUR AU - Mrazek, M. AU - Mossialos, E. PY - 2003 DA - 2003// TI - Stimulating pharmaceutical research and development for neglected diseases JO - Health Policy VL - 64 UR - https://doi.org/10.1016/S0168-8510(02)00138-0 DO - 10.1016/S0168-8510(02)00138-0 ID - Mrazek2003 ER -